{
  "docId": "019de076-b8a1-76db-a88b-3941d3b29d31",
  "docSlug": "785649d6ad3bf1f87bd264132bed44c1",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 25 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 25,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 2,
  "notes": "The slide uses a split-column layout to contrast two phases of a clinical trial.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b8a1-76db-a88b-3941d3b29d31/13",
  "deckHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31",
  "deckJsonHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31.json",
  "deckAnchorHref": "/decks/019de076-b8a1-76db-a88b-3941d3b29d31#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.44,
        "x": 0.28,
        "y": 0.84
      },
      "kind": "callout",
      "text": "Initial Phase 1b Data Read-Out Expected in 1Q2024",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca0b3cb0-4007-4614-8d2b-cd833fc2a820",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.96,
        "x": 0.02,
        "y": 0.28
      },
      "kind": "framework",
      "text": "Phase 1a vs Phase 1b comparison",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f110570-07ba-4e94-95cd-71b489015150",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "Enrolling patients with platinum-resistant, ARID1a mutated ovarian cancer (target population)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6b52ce9d-8756-4bae-9b04-7ed73e67cac4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.35,
        "y": 0.22
      },
      "kind": "source-note",
      "text": "Clinicaltrials.gov NCT05226507",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20d260aa-3967-462d-bf1d-000134401f4a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "NXP800: Phase 1b Underway, Fast Track Designation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b279f0b-598f-44fa-842b-f6c5ccca06b5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "537d1b83-f1b3-4859-bb81-6c4511f98d54",
      "evidence": "paragraph/paragraph: Enrolling patients with platinum-resistant, ARID1a mutated ovarian cancer (target population)",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "e0fb7553-482c-4197-9e78-97028a1bf977",
      "evidence": "Split-column layout comparing Phase 1a and Phase 1b trial parameters.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 13,
      "from": 9,
      "beatId": "e517dce6-8161-47a1-8122-29fab4f84ad6",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Clinical results and Phase 1b update for NXP800",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "091b1497-af72-44f0-adc3-01a8fe42e431",
      "evidence": "Substantial Antitumor Activity in ARID1a-Mutated Ovarian Carcinoma Xenografts",
      "position": 0,
      "objective": "Highlight the need for new cancer treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 21,
      "from": 12,
      "name": "Voice Of Customer",
      "slug": "51-voice-of-customer",
      "bestFor": "Product strategy, customer experience, market research",
      "matchId": "d812f16f-0b55-4efb-bb30-cddbdb9254e4",
      "evidence": "NXP800 Potential Opportunity in Multiple Cancers and NXP900 Potential Market Opportunity",
      "position": 1,
      "objective": "Show market potential for NXP800 and NXP900",
      "structure": "What Customers Say (Verbatim) -> The Pattern Across Voices -> The Insight -> The Response",
      "confidence": 0.6,
      "description": "Let customer quotes and feedback drive the narrative and validate the insight"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}